Targeting integrin α10β1 in Aggressive Cancer

Time: 11:00 am
day: Day Two


  • Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin α10β1
  • TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triplenegative breast cancer models